Clinical trials: Carcinoma of Prostate (Disorder)
Advanced Cancers
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
The goal of this clinical research study is to find the highest tolerable doses of the combinations of lenalidomide and other drugs that can be given to patients with advanced cancer.
- Trial name
- NCT01183663
- Testing
- Lenalidomide, Bevacizumab, Sorafenib
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- M.D. Anderson Cancer Center
Venous Thromboembolism (VTE)
Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners
Patients with cancer are at a significantly increased risk of experiencing a venous thromboembolism (VTE). VTE is defined by a blood clot in the leg or lower extremity (deep vein thrombosis) or a blood clot in the lung (pulmonary…
- Trial name
- PRACTISE (NCT03965741)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban(Eliquis), Pradaxa (Dabigatran etexilate)
- Where
- Sweden
- Volunteers
- 97,765 people
- Sponsor
- Bayer
Prostate Cancer, Biochemical Recurrence
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or rezvilutamide in combination with ADT in prostate cancer patients with…
- Trial name
- NCT05753566
- Testing
- Rezvilutamide, Androgen deprivation therapy (ADT), SRT
- Where
- 2 sites in China
- Volunteers
- 96 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Neoplasia Prostate
PALLiON - PALLiative Care In ONcology
A major concern in today's oncology is the complexity of treatment that increases costs. A main contributor is the increasing use of chemo- and radiotherapy during end of life (EoL: the last 12 months of life).
- Trial name
- PALLiON (NCT03088202)
- Testing
- Educational program, Standardized care pathways, Early palliative care
- Where
- 12 sites in Norway
- Volunteers
- 659 people
- Sponsor
- Oslo University Hospital
Prostatic Neoplasm, Survivorship
Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness
Frailty is one of the main reasons older adults lose independence. Frailty describes a reduced ability to withstand stress on the physiological scale, or a reduced physiological reserve.
- Conditions
- Prostatic Neoplasm, Survivorship, Frailty, Aging
- Trial name
- ADRIAN (NCT05968144)
- Testing
- Dietary recommendations, Time-restricted eating
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Maryland, Baltimore
Prostate Cancer
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).
- Trial name
- NCT04631744
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
The objective of this study was to evaluate the safety profile of ELIGARD® in ethnic Asian prostate cancer patients.
- Trial name
- NCT03035032
- Testing
- Leuprolide
- Where
- 19 sites in Hong Kong, Indonesia and 6 more
- Volunteers
- 107 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Prostate Cancer
Computer Planned Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Computer systems that allow doctors to create a 3-dimensional picture of the tumor in order to plan treatment may result in more effective radiation…
- Trial name
- NCT00003104
- Testing
- radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Performance Evaluation of the AMS CONTINUUM™ Device
1. To assess the safety of using the CONTINUUM™ device by monitoring the side effects and complications associated with the Device following a radical prostatectomy. 2.
- Trial name
- NCT00894933
- Testing
- CONTINUUM™
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- American Medical Systems
Prostate Cancer, Fluorocholine
18F-fluorocholine and 18F-fluoride PET in Prostate Cancer
Prostate cancer remains to be a public health problem around the world. For patients with prostate cancer, diphosphonate bone scintigraphy (BS) and pelvic tomographic imaging are major imaging tools to evaluate the disease…
- Trial name
- NCT04340765
- Testing
- 18F-fluorocholine
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Advanced or Metastatic Solid Tumors, Breast Cancer
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT05787587
- Testing
- IDE-161, Pembrolizumab
- Where
- 27 sites in United States
- Volunteers
- 216 people
- Sponsor
- IDEAYA Biosciences
Prostate Cancer
Studying Stored Samples From Patients With Localized Prostate Cancer Treated on Clinical Trial NCI-00-C-0154
RATIONALE: Studying samples of blood in the laboratory from patients before and after treatment may help doctors learn more about the effects of the treatment on cells.
- Trial name
- NCT00535834
- Testing
- diagnostic procedure, molecular diagnostic method, protein expression analysis
- Volunteers
- 48 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Kidney Disease, Radiation Nephropathy
Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial
The goal of this observational study is to determine the impact of 177Lutetium-Prostate Specific Membrane Antigen (PSMA) Radioligand Therapy (177Lu-PSMA-RLT) on kidney function over time.
- Conditions
- Kidney Disease, Radiation Nephropathy, Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Trial name
- KiRi (NCT06720532)
- Testing
- characterization of renal function., Handgrip strength test, Questionaires
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Hannah Schaefer
Prostate Cancer
Hypofractionation Proton Beam Therapy With Concurrent Treatment of Prostate and Pelvic Nodes for Prostate Cancer
The study is to examine a moderate hypofractionation regimen of proton beam therapy for high risk or unfavorable intermediate risk prostate cancer.
- Trial name
- NCT02874014
- Testing
- Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Mayo Clinic
Prostate Cancer (Post Prostatectomy)
Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy
Prostate cancer patients with high-risk features who undergo radical prostatectomy (RP) are at a significant risk of biochemical recurrence (BCR) and disease progression.
- Trial name
- ARMOR (NCT07711314)
- Testing
- Rezvilutamide Tablets
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer
Radium-223 in Combination With Enzalutamide
This study aims to determine the safety and tolerability of Radium-223 when administered in combination with enzalutamide in progressive metastatic castrate-resistant prostate cancer.
- Trial name
- NCT02225704
- Testing
- Radium-223 and enzalutamide
- Where
- 7 sites in Ireland
- Volunteers
- 45 people
- Sponsor
- Cancer Trials Ireland
Breast Cancer, Healthy Volunteer
An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin
Background: Blister fluid contains many of the same biomarkers (substances that can be used to determine the effects of certain kinds of treatments) as blood and urine samples, particularly regarding changes in the skin.
- Conditions
- Breast Cancer, Healthy Volunteer, Prostate Cancer
- Trial name
- NCT00923104
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Advanced/Metastatic Solid Tumor
KZR-261 in Subjects With Advanced Solid Malignancies
A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZR-261, as well as identify the recommended Phase…
- Trial name
- NCT05047536
- Testing
- KZR-261
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Kezar Life Sciences, Inc.
Prostate Cancer
Validation Study on the Impact of Decipher® Testing - VANDAAM Study
The primary purpose of this study is to determine whether a tumor test recently developed by GenomeDx Biosciences known as Decipher® can predict aggressive prostate cancer with the same accuracy in African-American men (AAM) as…
- Trial name
- VANDAAM (NCT02723734)
- Testing
- Decipher® Testing
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Neoplasms, Ovarian Neoplasms
Massage Therapy for Cancer-Related Fatigue
The purpose of this study is to develop methods for studying the effect of bodywork therapy on symptoms of fatigue in patients undergoing cancer chemotherapy.
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms
- Trial name
- NCT00039793
- Testing
- Moderate-intensity and low-intensity bodywork therapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.